Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

CELGENE CORPORATION (CELG)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Celgene Corporation : to Announce Third Quarter 2017 Results

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/04/2017 | 10:25am CET

Release date- 03102017 -

SUMMIT, N.J. - Celgene Corporation (NASDAQ: CELG) will host a conference call and live audio webcast on Thursday, October 26, 2017 at 9 a.m. ET to discuss third quarter 2017 financial and operational results.

The webcast can be accessed from the Investor Relations page at www.celgene.com.

Celgene will also host a webcast of an investor event at the MSParis2017-7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) - American Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Meeting on Saturday, October 28 at 6:00 p.m. CEST (12:00 p.m. ET). Members of Celgene's management team and clinical investigators will discuss the data presentations at the ECTRIMS Meeting. The event will be webcast live and will be available in the Investor Relations section of the Company's web site at www.celgene.com.

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Forward Looking Statements

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words 'expects,' 'anticipates,' 'believes,' 'intends,' 'estimates,' 'plans,' 'will,' 'outlook' and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

Contact:

Tel: 908-673-9969

(c) 2017 Electronic News Publishing -, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CELGENE CORPORATION
02/21CELGENE CORPORATION : - OTEZLA Phase III Data Showed Significant Improvements in..
AQ
02/21CELGENE : Shaky mid-stage data wont halt Celgenes plans for Otezla
AQ
02/21CELGENE : Amunix announces XTEN and ProTIA technology licensing agreement with C..
AQ
02/20CELGENE CORP /DE/ : Entry into a Material Definitive Agreement, Creation of a Di..
AQ
02/20Celularity Announces $250M in Funding to Deliver Treatments for Cancer Inflam..
AQ
02/20CELGENE : Reports Positive Data on Dermatology Drug Otezla
AQ
02/20CELGENE : reveals strong P3 Otezla data in rare inflammatory condition
AQ
02/19CELGENE CORPORATION : Elects John Weiland to Its Board of Directors
AQ
02/17CELGENE : OTEZLA® (Apremilast) Phase III Data Showed Significant Improvements in..
PU
02/17CELGENE : OTEZLA® (Apremilast) Phase III Data Showed Significant Improvements in..
BU
More news
News from SeekingAlpha
02/21YOUR DAILY PHARMA SCOOP : Buy Heron At Dips, Aimmune Positive Data, Voyager And .. 
02/21Celgene gets antitrust clearance for Juno buy 
02/20BIOTECHS : Still Well Placed For More Gains 
02/20Celgene's Otezla reduces oral ulcers in late-stage study 
02/19Healthcare In Transition 
Financials ($)
Sales 2018 14 810 M
EBIT 2018 8 539 M
Net income 2018 5 625 M
Finance 2018 346 M
Yield 2018 -
P/E ratio 2018 13,42
P/E ratio 2019 11,08
EV / Sales 2018 4,74x
EV / Sales 2019 3,82x
Capitalization 70 592 M
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 31
Average target price 125 $
Spread / Average Target 34%
EPS Revisions
Managers
NameTitle
Mark J. Alles Chairman & Chief Executive Officer
Scott Andrew Smith President & Chief Operating Officer
Peter N. Kellogg Executive VP, Chief Financial & Accounting Officer
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Rupert J. Vessey President-Research & Early Development
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION-9.55%70 592
JOHNSON & JOHNSON-7.19%357 710
NOVARTIS-3.37%226 667
PFIZER-2.84%216 135
ROCHE HOLDING LTD.-9.37%207 826
MERCK AND COMPANY-0.50%153 359